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 Atherosclerosis is a complex, multifactorial, inflammatory disease involving 
cholesterol, endothelial cells, smooth muscle cells, macrophages and platelets. 
Atherosclerosis, and the associated cardiovascular diseases it contributes to, has been a 
growing health care and economic concern over the last 50 years. Bioactive peptides 
found in fermented milk have been shown to have cardio and athero-protective effects, 
but their mechanism has not been fully elucidated. The objective of this study was to 
test individual components of milk fermentation and macrophage conditioning in order 
to determine how fermented milk bioactive peptides best exert their effects. This study 
shows that protein secretions from bacteria, whole and fermented milk ferments and 
supernatants from macrophages conditioned with fermented milk do not down-regulate 
inflammatory activity in cultured endothelial cells, however moderate anti-inflammatory 
nitric oxide (NO) production by cultured endothelial cells was seen with peptides derived 
from the milk β -casein sequence, warranting further study. 
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1 - Introduction 
1.1 - Cardiovascular Disease 
According to the Public Health Agency of Canada, cardiovascular disease (CVD) is a term 
that refers to multiple diseases of the heart and circulatory system of the lungs, the 
brain, kidneys or other parts of the body (Public Health Agency of Canada, 2013). The 
most recent findings from the Canadian Heart and Stroke Foundation found that 1.3 
million people in Canada suffer from chronic CVD or atherosclerosis, with another 
300,000 affected by the symptoms of stroke (Dai, Bancej et al. 2009).  
Cardiovascular disease can, generally, be divided into 6 categories (Public Health 
Agency of Canada, 2013). First and foremost, the most common sub-type of CVD in 
Canada and other industrialized nations is ischemic heart disease.  Ischemia presents 
itself when blood can no longer circulate properly to the heart muscle. The lack of blood 
supply manifests from a blockage created through a thromboembolism or 
atherosclerotic plaque buildup. Symptoms generally present themselves through angina 
(acute chest pain) or dyspnea (shortness of breath). Complete blockage can result in 
insufficient oxygen leading to necrosis and myocardial infarction, most commonly 
referred to as a “heart attack”.  The second subtype is known as cerebrovascular disease 
which can lead to a stroke. Strokes occur when the blockage occurs in the brain, instead 
of cardiac muscle. Due to the lack of oxygenation to the brain, symptoms can be far 
reaching and severe, depending on the area of the brain affected (Macciocchi et al. 
1998). Blockage of less than 60 minutes (Albers et al. 2002) is referred to as a “transient 




the damage that results is severe and long term, with the most devastating results 
arising when blocked blood vessels burst (Fleming et al. 1999). The third subtype, and 
last one directly related to issues with circulation, is peripheral vascular disease. This 
disease most typically causes issues in circulation in the legs, manifesting itself as leg 
pain, and is due to blockage associated with thrombosis or atherosclerotic build up. Left 
untreated the issues can progress to ischemia, potentially ending in ulceration, necrosis 
and gangrene, especially in diabetics (Edmonds et al. 2006). The latter three types of 
cardiovascular disease, while important, do not directly relate to our research. They 
consist of heart failure, rheumatic heart disease and congenital heart disease. They deal 
mostly with issues of heart muscle proper, as opposed to the circulation supplying them. 
  Of those affected, approximately 70,000 people every year die due to CVD 
complications, or 1 every 7 minutes (Statistics Canada, 2011).  In Canada alone, the 
combination of disease prevalence and mortality rate lead to an egregious economic 
burden of over $20.9 billion (Conference Board of Canada, 2010). Since 1952, the 
cardiovascular death rate has declined more than 75% largely due to research advances 
in surgical procedures, drug therapies, and prevention efforts (Statistics Canada, 2011c). 
This however, has not completely eliminated the risk associated with CVD. In fact as of 
2011, CVD accounted for 29% of all deaths in Canada, 28% of all male deaths and 29.7% 
of all female deaths (Stats Canada, 2011c). As ours and other countries continue to 
advance towards a more CVD prone modern lifestyle consisting of sedentary behaviour 
and high fat diets, it is thought that rates of CVD and atherosclerosis will increase 




atherosclerosis will be the highest disease burden in most of the developed nations 
around the world. (Jamison et al. 2006)  
1.2 – Obesity and Risk Factors for Cardiovascular Disease  
 Obesity is a complex multifactorial disease that develops from an interaction of 
genotype and environment. Among the factors that make obesity such a major health 
concern are the risk factors that promote the onset of atherosclerosis and 
cardiovascular disease. While atherosclerosis, CVD and their precursor, endothelial 
dysfunction, are not unique or specific only to individuals with obesity, there are risk 
factors present in obesity that more readily promote the initiation of a dysfunctional 
endothelium, thereby also promoting the progression of atherosclerosis. These factors 
include atherogenic dyslipidemia (increased triglycerides and LDL and decreased HDL 
levels), insulin resistance, a pro-inflammatory state and a prothrombotic state (Grundy, 
2002). Dyslipidemia occurs because of the increased consumption and overconsumption 
of a diet high in saturated fats. Several studies have shown that high levels of 
triglyceride associated with visceral obesity and type 2 diabetes mellitus lead to an 
increase in very-low density protein and apoprotein B (apoB) containing lipoprotein 
particles (Lewis et al. 1995). There is a positive correlation between levels of apoB in the 
blood, waist circumference, insulin resistance and cardiovascular disease risk (Lemieux 
et al. 2000). Individuals who are obese or are at risk with the metabolic syndrome tend 
to, though not always, consume high fat/ high sugar diet, summarily being supplied with 
both external sources of glucose and free fatty acids (FFA) and internal FFA that are 




increase in FFA concentration in the blood interferes with the ability of skeletal muscle 
to respond to insulin and uptake glucose, as FFA competes with glucose as an energy 
substrate (Boden et al. 1991). This leads to increased levels of both glucose and insulin in 
the blood, conditions known as hyperglycemia and hyperinsulinemia respectively. 
Hyperinsulinemia, and the increased concentrations of insulin that are its namesake, 
have the ability to alter endothelial function in a pro-inflammatory manner (Festa et al. 
2000). These increased insulin levels lead to endothelial dysfunction, altered fatty lipid 
deposition, onset of the atherosclerotic process and stimulated proliferation of vascular 
smooth muscle (Arcaro et al. 2001; Sidossis et al. 1999; Abhijit et al. 2013).  Each of 
these factors acting together are what produce the disease known as atherosclerosis. As 
well as damaging the endothelium, insulin, through the MAPK signaling pathway, can 
cause endothelial cells to express plasminogen activator inhibitor-1 (PAI-1) and cell 
adhesion molecules such as Vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular adhesion molecule-1 (Madonna et al. 2004). 
  ICAM-1 and VCAM-1 are similar in the sense that they are both adhesion molecules 
found on the surface of the endothelial lining when endothelial cells are exposed to pro-
inflammatory conditions. In the case of atherosclerotic progression, inflammation of the 
endothelium works on a microscopic level. Damage occurs due to modulations in the 
shear stress applied to a vascular branch point or through exposure to oxidized low-
density lipoproteins (oxLDL) (Libby et al. 2002). This damage causes monocytes and 
lymphocytes, the harbingers of inflammation, to crowd to the damaged endothelium in 




atherosclerosis being an inflammatory disease. VCAM-1 and ICAM-1 bind directly to 
molecules on monocytes and leukocytes to continue the inflammatory signaling through 
the cells and facilitate movement of leukocytes and monocytes through the 
endothelium where they become trapped and begin production of the fatty streak 
(Barriero et al. 2002). This inflamed, adhesive, pro-atherogenic or “sticky” dysfunctional 
endothelium is required for formation of the fatty streak and, later, progression of 
atherosclerosis.  
The sum total of these risk factors promoting obesity, diabetes and 
cardiovascular disease are typically referred to as the “metabolic syndrome” (Fulop et al. 
2006). The metabolic syndrome is a complex of interrelated factors for cardiovascular 
disease (CVD) and diabetes. These factors include dysglycemia, raised blood pressure 
(BP), elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels 
and obesity, particularly central adiposity (Alberti et al. 2009). Importantly, it has been 
suggested, and in many cases shown, that obesity, diabetes, or simply the 
overconsumption of “unhealthy foods” leads to the inflammatory processes of 
atherosclerosis (McGill et al. 2002; Fekete et al. 2000; Pirro et al. 2001). The high 
amounts of triglyceride in the blood lead to increased amounts of low and very low 
density lipoprotein which are then available to be oxidized into LDL. The high amounts of 
glucose and the insulin released to deal with these high glucose levels can damage the 
endothelial lining of the blood vessels, causing an immediate and potentially insidious 




becomes more and more dysfunctional finally resulting in the onset of the 
atherosclerotic process. 
1.3 - Atherosclerosis 
Initially believed to be a disease solely associated with an increase in serum 
lipids, it has actually been shown that atherosclerosis is inflammatory in origin (Epstein 
and Ross 1999). This brought into question what the causative factors that lead to the 
disease’s progression might be. However, understanding that atherosclerosis is no 
longer solely associated with serum lipids should not in any way diminish their 
importance (Libby, 2006). Though not necessarily integral to the initiation of 
atherosclerotic processes, the increased levels and eventual modification of serum LDL is 
vital to the progression of atherosclerosis through their role in foam cell development 
(Aldrovandi and O'Donnell 2013).  
To begin progression towards atherosclerosis the endothelium must become 
dysfunctional enough to allow leukocytes to invade past the endothelial barrier and 
initiate plaque buildup (Libby et al. 2002). Endothelial dysfunction is the primary process 
that leads to the initiation of the atherosclerotic plaque. Healthy endothelium is smooth, 
mediating the flow of blood and its constituent cells throughout the body. The barrier 
created by the endothelial wall, consisting of the endothelial cells separating the lumen 
of the vessel from the smooth muscle cells that control vessel diameter, forms a 
semipermeable membrane that mediates diffusion and diapedesis of circulating 




joined through the use of tight junctions, adherens and gap junctions (Yuan and Rigor, 
2012). These junctional complexes stop most material, making exceptions for small 
proteins and leukocytes like macrophages and dendritic cells. Since our circulatory 
system is one of such intricate balance, it stands to reason that the permeability of the 
endothelium and the smooth muscle beneath it each have a role to play during 
physiologic stress. In fact, for every increase and decrease in BP, there is a physiologic 
reaction seen in the vessels. Besides overall survival, strict regulation of the forces acting 
upon the endothelial cells allows our cells to maintain their homeostatic balance. It is 
the imbalance of these forces that leads to dysfunction. 
In order to maintain ideal homeostatic conditions, including the release of 
regulatory cytokines, our blood vessels must be exposed to laminar flow. Laminar flow is 
a phenomenon seen in liquids moving through a smooth, unobstructed tube. The liquid 
moves in layers of varying speeds, from fastest in the centre of the tube and slowing as it 
moves closer to the vessel wall. Laminar flow imparts a certain amount of shear stress 
upon the endothelium that causes constitutive release of homeostatic molecules, such 
as the vasodilator nitric oxide (NO) (Malek et al. 1999) which, among other things, acts 
to suppress the activation of inflammatory transcription factors. Without the 
suppressive effects of NO, the endothelium begins to produce the adhesion molecules 
ICAM-1, VCAM-1, e-selectin and p-selectin (De Caterina et al. 1995). These act to cause 
firm adhesion of leukocytes, in the case of VCAM-1 and ICAM-1, or mediate leukocyte 
rolling along the endothelium, in the case of e-selectin and p-selectin as well as causing 




(IL-8), macrophage colony stimulating factor (MCSF), monocyte chemoattractant protein 
1 (MCP-1) and regulated on activation, normal T cell expressed and secreted (RANTES) 
(Libby, 2006).  Respectively, the interleukins (IL-6 & IL-8) mediate overall inflammatory 
cell signaling, MCSF stimulates macrophage recruitment, MCP-1 attracts monocytes to 
inflammatory sites and RANTES activates and recruits T-l ymphocytes.   When BP rises or 
when flow reaches natural branch points present in the circulatory system, laminar flow 
is interrupted and turbulence becomes present within the artery. This turbulence causes 
oscillating increases and decreases in BP and as such abrogates the natural production 
and release of NO (Malek et al. 1999). NO is an anti-inflammatory vasodilator that acts 
to protect endothelial cells when the cells come under stress. Decreasing the levels of 
NO being released by the endothelial cells is a major contributing factor to the initiation 
and progression of endothelial dysfunction and atherosclerosis (Matthys and Bult, 1997; 
Schachinger et al. 2000). The up-regulation of inflammatory cytokines and adhesion 
molecules causes the endothelium to morph from a smooth passage, mediating laminar 
flow, to a sticky trap, causing circulating leukocytes to adhere to the surface of the 
endothelium and make their way inside the vessel wall. Transient accumulations of 
leukocytes within the walls of vessels at sites of turbulent flow and endothelial 
dysfunction lead to the production of the hallmark of atherosclerosis, the fatty streak 
(Libby et al. 2002).  
 Through normal metabolic processing, free radicals (substances with unpaired 
valence electrons that have an oxidizing effect), are produced by the body and serve to 




process occurs on an LDL molecule, the LDL becomes activated into the inflammatory 
ox-LDL molecule; this is the version of LDL that macrophages react to and consume, a 
process that turns them into foam cells (Stancu et al. 2012). An increase in consumption 
of fatty foods leads to an increase in serum triglyceride and LDL levels. This increase 
leads to an increased availability of LDL to be oxidized by the free radicals, leading 
eventually to an increase in foam cell production and accumulation. As ox-LDL molecules 
and monocytes circulate through our bodies, they both create and are attracted to the 
site of endothelial dysfunction (Valente et al. 2014). Ox-LDL promotes endothelial 
dysfunction and endothelial cytoskeletal remodelling, allowing for gaps to form in the 
endothelial barrier (Chouinard et al. 2008). It is through these gaps that ox-LDL infiltrate 
the blood vessels and begin to accumulate. Monocytes, on the other hand are attracted 
by the inflammatory cytokines released by the endothelial cells (Libby, 2006). Upon 
arriving at the site of dysfunction the monocytes stick to and roll along the endothelium, 
rather than bouncing off (Pober and Sessa, 2007). This rolling is mediated by the 
presence of E and P selectin; E-selectin and P-Selectin are membrane glycoproteins that 
are commonly expressed on cells that are affected by cytokines (Leeuwenberg et al. 
1992; Frenette et al. 1995). As they populate the endothelial surface, the blood vessels 
becomes sticky allowing travelling leukocytes to roll along the vessel wall. From there 
the leukocytes then interact with VCAM-1 and ICAM-1 which act as anchors on the 
luminal surface and allow for firm adhesion (Sima et al. 2009). Once firmly adhered, the 
leukocytes then are able to move into the vessel wall through a process known as 




cytoskeleton leading to cell contraction. This contraction creates enough of a gap 
between cells that leukocytes and LDL are allowed to infiltrate into and underneath the 
dysfunctional endothelium. Once they have infiltrated the endothelial barrier, the now 
trapped monocytes differentiate into macrophages that begin to release signaling 
cytokines that attract other monocytes to the sticky endothelium, facilitating further 
infiltration (Wang et al. 1988). Using scavenger receptors on their surface, these sub-
endothelial macrophages engulf ox-LDL, becoming activated foam cells, characterized by 
the creation of lipid droplets within the macrophages (Gerrity et al. 1981). The initial 
accumulation of foam cells under the endothelial barrier is known as the fatty streak, 
the hallmark of the atherosclerotic process.  
1.4 - Markers of Endothelial Dysfunction  
1.4.1 - Adhesion Molecules: ICAM-1  
 Intercellular Adhesion Molecule-1 (ICAM-1/CD54) is an adhesion molecule that 
plays an important role in leukocyte adhesion to the endothelium. During inflammation, 
e-selectin and p-selectin membrane glycoproteins levels increase causing the leukocytes 
that would normally bounce against the vessel wall to roll along it instead. In a similar 
fashion, expression of ICAM-1, which is present only at low levels during normal 
function, increases during inflammation (Hubbard and Rothlein, 2000). While rolling, the 
leukocytes come into contact with ICAM-1 which functions to firmly adhere the 
leukocytes to endothelial cells and mediate the movement of cells into the vessel walls.  
This molecule plays an important role in endothelial dysfunction, formation of the fatty 




1.4.2 - Adhesion Molecules: ICAM-2 
Intercellular Adhesion Molecule-2 (ICAM-2/CD102) is an adhesion molecule that 
plays an important role in regular systemic immunity. ICAM-2 is readily expressed on 
endothelial cells and functions as a receptor for lymphocyte function-associated antigen 
1 (LFA-1), much the same way as ICAM-1, on leukocytes, mediating their movement 
from the blood vessel lumen through the endothelial barrier (diapedesis) in non-
inflammatory conditions. ICAM-2 functions in much the same way as ICAM-1 but 
functions during the resting state and is typically unaffected by the presence of pro-
inflammatory mediators (de Fougerolles et al. 1991). E-selectin and p-selectin mediate 
leukocyte rolling along the endothelial barrier until binding of LFA-1 to ICAM-2 causes 
firm adhesion of the leukocytes to the endothelial barrier before mediating their entry 
into the vessel wall (Halai et al. 2014; Vanier and Nielsen, 2000) 
1.4.3 - Cytokines: MCSF 
 Macrophage colony stimulating factor (MCSF) is both a hematopoetic growth 
factor and inflammatory cytokine with important roles in hematopoiesis, angiogenesis, 
pregnancy, inflammation, bone growth and remodeling. With regards to endothelial 
function, MCSF is released by endothelial and smooth muscle cells in order to attract 
macrophages to the site of injury. MCSF is also readily expressed by macrophages and is 
an important inflammatory cytokine that differentiates monocytes that have been called 
to the site of inflammation into macrophages (Palucka et al. 2015). It also allows these 
macrophages to develop further into foam cells, which are the primary cell type present 




              1.4.4 - Cytokines: sICAM-1 
              Soluble ICAM-1 is the same as ICAM-1, except it has been cleaved from the cell 
surface (Champagne et al. 1998). Though the actual function of sICAM-1 has yet to be 
fully elucidated, it is associated with a diagnosis of CVD or atherosclerosis as the levels in 
the blood are always elevated in those with disease (Ridker et al. 1998). It can exist in 
dimeric, monomeric or truncated forms, the latter two having less binding affinity for 
LFA-1 (Meyer et al. 1995; Jun et al. 2001). sICAM-1’s ability to bind to LFA-1 might have 
designated it as a potential therapy in blocking the adhesion of LFA-1 to membrane 
bound ICAM-1; however it has been found that sICAM-1 activates inflammatory 
cascades (Lawson and Wolf, 2009).  sICAM-1’s exact effects require more research, and 
therefore its overall role in atherosclerosis and cardiovascular disease has yet to be 
revealed.  
1.4.5 - Chemokines: MCP-1 
 Monocyte Chemoattractant Protein – 1 (MCP-1) is a key chemokine involved in 
the inflammatory response. It is released by many different cell types in response to 
many types of stimuli including oxidative stress and other cytokines. MCP-1 is very 
important in leukocyte recruitment to areas of inflammation and is abundantly released 
from endothelial cells (Rollins et al, 1990). Its relation to atherosclerosis was 
demonstrated through genetic ablation of the CCL2 gene, which encodes this protein, 
with the resultant mice having a marked reduction in fatty streak formation (Deshmane 





1.5 - Anti-Inflammatory Effects of Milk Ferments 
It has been shown that consumption of fermented milk products has a 
suppressive effect on cardiovascular disease and atherosclerosis (Sonestedt et al. 2011), 
and research conducted at UOIT has shown that fermented milk products cause a 
decrease in inflammatory cytokine production in treated gut epithelial cells (Wagar et al, 
2009). As milk products are fermented by lactobacilli, many potentially bioactive 
compounds are released. It is through these bioactive compounds that fermented milk 
products may exert either a direct or an indirect effect upon the body, leading to a 
noticeable decrease in CVD risk (Panagiotakos et al. 2010). These compounds can 
include specific bioactive proteins, peptides, lipids and carbohydrates, which will each 
act within the body to elicit different biological responses. A list of known bioactive 
compounds was compiled by Young W. Park (2009), with their known biological activity. 
During the course of our investigation we were attempting to elucidate novel bioactive 
peptides and as such peptides will be the only molecules discussed. Peptides are defined 
as a compound containing two or more amino acids bonded in sequence (The Concise 
Oxford Dictionary, 1991). 
A cohort study undertaken by Sonestedt et al. (2011) which looked at 26,445 
individuals “without a history of myocardial infarction, stroke and diabetes” found an 
association between cardiovascular disease and dairy product consumption and 
observed effects of fermented milk products on CVD risk. Subjects self-reported, using 
an extensive questionnaire, which included information on lifestyle, socioeconomic and 




diseases (Sonestedt et al. 2011). Sample groups were divided based first on alcohol 
consumption (consumers vs. zero-consumers) and then again into gender specific 
quintiles based on their self-reported dietary intakes. Over the course of a 12 year follow 
up, 2520 CVD events occurred out of the 26,445 individuals originally surveyed. Due to 
the access investigators had to self-reported diet and lifestyle information, they could, 
as never before, determine how dietary consumption of non-fermented milk, fermented 
milk, cheese, butter and cream relates to CVD risk factors. To do this they looked at 
blood pressure (diastolic and systolic), triglycerides (TG), high density lipoprotein (HDL-
C), low density lipoprotein (LDL-C) and homeostatic model assessment (HOMA) index, 
which is a method of estimating insulin sensitivity, in 4535 individuals who were a 
further subset of the initial study group. What they noticed during this study is that 
consumption of unfermented milk caused significant increases in all of the above risk 
factors except HDL-C, which saw a decrease. This is an issue as HDL-C is associated with 
good heart health. They then looked at the risk factors of individuals after consumption 
of fermented milk as well as cheese, butter and cream.  It was shown that in the 
individuals that consumed fermented dairy products, there was a significant decrease in 
the risk factors associated with CVD and atherosclerosis, as well as a significant increase 
in the levels of HDL. Therefore, it was suggested that consumption of fermented dairy 
products, not their unfermented precursor, is inversely correlated to CVD risk. 
Interestingly, it was shown that, as compared to non-fermented milk, consumption of 
cheese, butter and cream showed many of the same beneficial effects as fermented 




they are typically higher in saturated fats, this addresses the fact that these dairy 
products have beneficial cardio-protective effects and their complete dietary effects 
cannot be assessed by their levels of a single nutrient (in this case, saturated fatty acid). 
Corroborating this information, Wagar et al. (2009) presented a study in which 
they treated the intestinal epithelial cell line (IEC) HT-29 with fermented dairy products 
and looked at the alterations in the expression and release of the inflammatory 
cytokine, IL-8. The cells were treated with either 0, 1.6 ng/mL, or 160 ng/mL of LPS to 
induce IL-8 production and 5x104, 5x106 and 5x108 –CFU/mL of L. rhamnosus ferments 
to observe the effects on gut epithelial cells. A significant decrease in IL-8 levels was 
reported compared to cell controls at 3 different effective concentrations. Every 
concentration served to decrease the IL-8 levels in the HT29 IEC being treated. (Wagar et 
al. 2009). 
Given that consumption of fermented dairy products has a reported inverse 
correlation to CVD and atherosclerosis and that their presence serves to abrogate 
inflammatory cytokine release at the level of the intestinal epithelium, the proposed 
next step is to explore the possible systemic effects of bioactive peptides from 
fermented milks on the endothelial cells of the blood vessels and propose a mechanism 
whereby fermented milk consumption would decrease CVD risk.   
1.6 - Bioactive Peptides 
Milk proteins consist of 80% casein and 20% whey. Whey is the liquid remaining 




1996). Whey protein, while historically considered a waste product or used as animal 
feed, has gained a lot of traction in its use as a fitness supplement when concentrated 
and isolated from the other proteins in the liquid suspension. On the other hand, casein 
proteins make up a majority of the dry matter protein weight within milk. When looking 
at the potential of dairy products to exert a protective/anti-inflammatory effect it is 
important to assess the effects of both whey and casein in order to construct a possible 
mechanism of milk’s, and it is associated dairy products, action within the body. Whole 
whey and casein protein have both been associated with promoting cardiovascular 
health and in fact seem to both have similar effects on blood pressure, with whey 
protein also showing potential serum lipid lowering effects (Phelan and Kerins,; Fekete 
et al. 2013). Gender, diet, bacterial strain, experimental method and exact temperature 
can impact whether or not peptides will have a biological effect (Fuente et al. 2002). 
Certain cheeses exert a cardio-protective effect only in women, while showing no effect 
in men, and peptides that show anti-inflammatory or protective effects in vitro might 
have no effect in vivo and vice versa (Fekete et al. 2013; Sonestdedt et al. 2011). While it 
has been shown that whey and casein have beneficial cardio protective and blood 
pressure lowering effects, and while it seems that a few studies have made progress in 
discovering their method of action, the studies are not as strong as they could be due to 
small sample sizes (Fekete et al. 2013).    
Though the action of bioactive peptides has yet to be completely elucidated, 
there are at least 3 separate proposed mechanisms by which it is thought that certain 




inhibition (Donkor et al. 2007; Stressler et al. 2013). Angiotensin Converting Enzyme 
(ACE) is an enzyme found in the blood that converts angiotensinogen to angiotensin I 
and then to angiotensin II, a potent vasoconstrictor. The precursor protein, 
Angiotensinogen, is converted to angiotensin I when acted upon by renin.  Though 
angiotensin I has no real biological activity, it plays an incredibly important role in the 
body: precursor to angiotensin II. Angiotensin II is created when angiotensin converting 
enzyme removes two C-terminal residues from angiotensin I. This removal changes a 
benign protein into an incredibly potent vasoconstrictor. Its primary method of action is 
to cause the tonicity of the vessels themselves to change, while also promoting the 
release of aldosterone which acts to increase blood pressure by increasing the 
resorption of sodium and water by the kidney.  ACE also has functions in the production 
of bradykinin; bradykinin is a potent vasodilator that functions to decrease the tonicity 
of the vessels by causing release of prostacyclin and nitric oxide (Palmer et al. 1987). ACE 
acts to remove C-terminal dipeptides from bradykinin, similar to its action upon 
angiotensin II, thereby inactivating it and blocking its vasodilatory role. Through this 
action angiotensin converting enzyme also acts to promote vasoconstriction and an 
increase in blood pressure. ACE inhibition, then, negates vasoconstrictive actions while 
promoting the release of bradykinin and NO. Studies have suggested that milk ferment 
peptides may exert cardioprotective effects through have ACE inhibitory activity (Donkor 
et al. 2007; Fekete et al. 2013; Papadimitriou et al. 2007).  
The kinds of novel peptides that are released in the process of fermenting milk 




al. 2009). There are two peptides produced by Lactobacillus helveticus and 
Saccharomyces cerevisiae that have routinely been shown to have ACE inhibitory activity 
and to play a role in the increased release of NO; these peptides are the lactotripeptides 
Isoleucyl-Prolyl-Proline (IPP) and Valyl-Prolyl-Proline (VPP) (Nakamura et al. 1995). These 
peptides have been shown to have ACE inhibitory activity and therefore decrease the 
conversion of angiotensin I to angiotensin II as well as prevent the breakdown of 
bradykinin (Nakamura et al. 1994). By doing so these peptides act in a similar fashion to 
ACE inhibitory drugs and protect and promote the release of NO. In fact Hirota et al. 
(2011) reported that IPP and VPP both showed effects on NO production within cultured 
endothelial cells and isolated rat aorta when compared to control. By promoting the 
release of NO, these peptides may increase vascular health by decreasing blood pressure 
and vascular tonicity. In addition, these bioactive peptides may increase the release of 
anti-inflammatory endothelial mediators (Hirota et al. 2011). By directly affecting the 
release of NO, specific bioactive peptides may have a mechanism to not only interfere 
with the effect of pro-atherogenic cytokines and adhesion molecules (such as 
angiotensin 2, ICAM-1 and MCP-1) but also have a way to protect cells in the vessels of 
healthy individuals, through the release of anti-inflammatory cytokines. Unfortunately, 
IPP and VPP have poor bioavailability when digested and while providing an excellent 
model for the potency of milk derived peptides, they make poor functional food 
supplements (Wuerzner et al. 2009). Further identification of novel peptides that may 
be incorporated into foods (making them functional foods) in order to assist in heart 




The other proposed functions of bioactive peptides is in interference with 
thrombus formation (Qian et al. 1995). It has been shown by Qian et al. that certain 
peptide fractions can interfere with thrombin-induced platelet aggregation. Thrombin is 
part of the final steps of the coagulation cascade, right before the production of fibrin 
allows for the formation of a stable clot. Inhibition of this process causes the clot to fall 
apart and therefore prevent less of a threat of clot formation and further damage 
caused by its disengaging from the vascular wall. There have also been reports 
(Haverstick et al. 1985) that certain peptide sequences can interfere with fibrinogen 
binding and platelet aggregation. 
1.7 - Research Objectives 
1.7.1 - Hypothesis  
 Given that there is a reported inverse correlation between CVD risk and 
fermented dairy product consumption, it is hypothesized that fermented dairy products 
have the ability to reduce atherogenic inflammatory immune activity through the 
production of bioactive peptides and their action on endothelial cells. This thesis 
describes an investigation into the anti-atherogenic effects of fermented dairy products 
on endothelial cell responses, directly through exposure to novel bioactive peptides and 
whole and filtered milk ferment, and indirectly, through conditioned macrophage 
supernatant. Studying endothelial responses to exposure to these different aspects of 
the fermentation process will allow us to understand at which point during fermentation 




through ferment acting on macrophages which then may release anti-inflammatory 
compounds). 
1.7.2 - Objectives 
The objective of my research project was to elucidate cellular and molecular 
mechanisms for the anti-atherogenic effects of bacterial secretome, whole and filtered 
milk ferment, conditioned macrophage supernatant and novel bioactive peptides on 
cultured primary human umbilical vein endothelial cells (HUVEC).  
The goal of my research was to identify any protective effects these compounds 
may have on blood vessel endothelium. In order to do this, we tested the effects of the 
milk ferments in many different ways on Human Umbilical Vein Endothelial Cells 
(HUVEC) to determine immunomodulatory and anti-inflammatory effects. The long term 
objective of this research is the characterization of peptides that may have systemic 
benefits in terms of alleviating CVD and atherosclerosis is part of a heart healthy diet. 
This would provide an accessible route for people to intake compounds in their diet that 
will assist them in disease prevention, management or rehabilitation in compliment to 









2 – Methods 
 2.1 – Media 
 The primary cell line of Human Umbilical Vein Endothelial Cells, HUVECs 
(Cedarlane), were grown, cultured and maintained in MCDB 131 media. The media was 
adapted from the human microvascular endothelial cell (HMEC) culture protocol from 
the Centres for Disease Control and Prevention (CDC). Initially the bottled MCDB 131 
media was supplemented with 10 mM L-glutamine (Gibco), 10% fetal bovine serum 
(Sigma), 1% penicillin/streptomycin (Pen/Strep) (Thermo), 1 μg/mL hydrocortisone 
(Sigma) and 10 ng/mL Endothelial Growth Factor (Sigma). Unfortunately, as the HUVECs 
on average require culture in larger vessels in order to achieve the required cell density 
for flow cytometric analysis, the amount of media that was necessary made this initial 
formulation expensive. We replaced the Bottled GIBCO MCDB 131 with powdered MCDB 
131 Sigma media. This also came pre-supplemented with the correct concentration of L-
glutamine. FBS was also replaced with iron supplemented fetal calf serum (FCS). The 
new supplemented media was tested by flow cytometry, both at rest and during 
activation, to ensure that its addition would cause no detrimental effects on the 
HUVECs. 
2.2 – Cell culture flasks 
The HUVEC cell line is an adherent cell line with a few special requirements. 
HUVEC cell lines are seeded in 75cm2 Corning cell culture flasks and passaged into 25 
cm2 cell culture flasks, 6-well plates or 0.32 cm2 96-well plates. Due to their adherent 




μg/cm2 collagen base-layer first. Collagen was dissolved in 0.1 M acetic acid before 
further dilution in phosphate buffered saline (PBS) to a volume capable of coating the 
bottom of the cell culture flask (6mL for T-75, 1.5mL for T-25, 600 μL for 6 well plate and 
100 μL for 96 well plate). This ensures there are no dry spots forming on the cell culture 
flask and allows for an even monolayer to form. Collagen coated flasks were then 
allowed to incubate at 37oC and 5% CO2 for ~ 2 hrs before being placed in a biosafety 
cabinet, under UV radiation overnight, to sterilize. Following overnight sterilization flasks 
can either be washed with PBS for use in cell culture or have additional PBS added for 
storage at 4oC. 
2.3 – Culture 
Following recommendations set in place by the American type culture collection 
(ATCC), HUVECs were seeded at a density of 5000 Cells/cm2 in order to propagate. 
Seeding at this density should lead to a confluent monolayer in approximately 8 days. 
Before culture, flasks were incubated for 30 minutes with cell culture media in order to 
ensure optimal growth. HUVECs were either seeded from frozen cell stock or after 
completion of the passaging protocol described below. Following either method of 
seeding, cells were kept at 37oC at 5% CO2 at all times, except for when media was to be 
changed. Spent media was removed every other day and replaced with fresh, 
supplemented MCDB 131 media that was first warmed in a water bath up to 37oC for 1 





2.3.1 – Initial Culture from Frozen Stocks 
HUVEC cell cultures were either stored in a freezer at -80oC or in liquid nitrogen, 
depending on the available storage space. Freezing at either temperature caused no 
noticeable alterations to cell viability of biomarker presentation. Cells cannot be seeded 
into well plates directly from frozen; they were first grown in 75 cm2 collagen coated cell 
culture flasks and passaged into the plates at the appropriate density. Upon removal 
from frozen containment, cell stock vials were wiped down with ethanol or isopropanol, 
in order to ensure sterility, and opened slightly (~1/4 turn) in a biosafety cabinet in order 
to relieve pressure before retightening for thawing. The vial was thawed quickly in a 
37oC water bath, without completely submerging the entire vial, again to ensure sterility 
by not allowing the water near the opening of the cryovial. Great care was taken to 
immediately remove the vial from the water bath the instant the last remnants of ice 
have melted, as leaving the vial in the water bath for too long can lead to less than 
optimal culture results. Cells were re-suspended in the cryovial to ensure all cells have 
been removed from the vial. Before pipetting the required amount of cells into the cell 
culture flasks. Media must be changed the following day in order to remove any harmful 
traces of DMSO from the cells. The cryovial was not centrifuged to pellet the cells out of 
the DMSO storage solution, as centrifuging at that stage would have been more harmful 






2.3.2 – Passaging 
Media was completely removed from each culture flask and cells were rinsed 
with PBS to ensure that no excess media remained that would neutralize the trypsin in 
the trypsin/EDTA (Thermo) mixture or the Accutase (Sigma) prior to passaging. Trypsin 
(Thermo) was an ideal choice when removal of the cells is required for experimentation 
as it required a shorter incubation time, but the harshness of the chemical was not well 
suited for cell passaging use. Accutase (Sigma), while taking longer, was much gentler, 
which made it the ideal choice for passaging the delicate HUVECs. A 2 mL volume of 
either trypsin or Accutase for every 25 cm2 of the cell culture flask was added to initiate 
the detachment of cells. For trypsin; 2mL was added for 2 minutes at 37oC before being 
neutralized with MCDB 131 supplemented media.  Neutralized cells can then be 
transferred into sterile Falcon tubes (Greiner Bio-One) and centrifuged at 300xg for 10 
minutes in order to remove dead cells and create a pellet of live ones. Pellets were re-
suspended in 1 mL culture media and 50 μL was removed for the trypan blue cell 
counting protocol described below. The alternative passaging methodology involved 
using Accutase. One inconvenience of Accutase was that it takes approximately 8x 
longer than trypsin to dissociate the cells from the culture flask, but the benefit was that 
it was gentler on the cells and required no neutralization step. Accutase was pipetted 
onto the PBS rinsed tissue culture flask in the same amounts as the trypsin method 
described above. Rather than 2 minutes at 37oC, though, the Accutase was left on the 
cells for 15 minutes up to an hour at room temperature. After ~15 minutes, the flasks 




Specifically the cells became round, compact, and much more separate, while still 
clinging to the bottom of the flask. The tissue culture flasks were then struck to dislodge 
the cells and the entire suspension was transferred into clean Falcon tubes. Again, 50 μL 
of the suspension was taken and used for Trypan blue exclusion assays.   The 50 μL of 
cell suspension was mixed thoroughly with Trypan Blue and ~15 μL of the final mix was 
pipetted into a hemocytometer. All cells were counted, but a second tally of blue (dead) 
cells was kept in order to determine viability. Using the Trypan Blue exclusion assay cells 
were counted and seeded into prepared collagen coated flasks at an appropriate 
amount to match the suggested 5000 cells/cm2 seeding density. Seeding at higher 
densities was, however, possible in order to form a monolayer more quickly. 
2.4 – Collagen Type I preparation protocol 
2.4.1 – Sigma Procedure 
 Type I collagen l arrived from Sigma as a fibrous bundle for reconstitution. 
In order to dissolve it properly, 0.1 M acetic acid was added to the collagen bundle to 
achieve a final working concentration of collagen solution of 0.1% (w/v). Once added, 
the mixture was allowed to stir for 1-3 hours at room temperature until completely 
dissolved. Once dissolved, the collagen was moved to a glass container with a layer of 
cholorform on the bottom and allowed to sit overnight for use beginning the following 
day. For our applications, 10 μg/cm2 of collagen solution per cell culture flask was 
optimal. If necessary, the collagen solution could be spread out with a cell scraper in 




solution was allowed to bind to the plates and flasks for several hours at room 
temperature, 37oC or overnight at 2-8oC. In order to ensure that the flasks remain 
sterile, the collagen coated flasks were placed into a biosafety cabinet overnight, under 
UV light. Before addition of media, coated flasks and plates were washed with either 
culture grade water or PBS before the introduction of media for one final incubation 
prior to the addition of cells for culturing. Additional flasks were stored in enough PBS to 
cover the flask and left at 4oC until ready to use.  
2.4.2 – Millepore  
Millepore collagen solutions came pre-made at a higher 2.92 mg/mL 
concentration. Therefore, the solution was diluted to a working concentration in PBS for 
dispensing 10 μg/cm2 of collagen to completely coat the flask/plate, leaving no dry spots 
at all. Once the collagen solution has been spread, the flasks were incubated at room 
temperature for 10-30 minutes. The solution was removed and the flasks were rinsed 
with PBS before adding media or cells. As above, flasks could be stored at 4oC with 
bottoms coated in PBS to prevent drying until they were necessary to use.  
2.5 – Cryopreservation 
Cell lines, ideally, should be frozen down at low passage numbers in order to 
maximize useful cell life. HUVEC cells are typically only viable for use in experimentation 
from passage numbers 2-5. Cells were passaged as noted above, before freezing down 
approximately 1 mL of cell suspension in each cryovial, at 106 cells/mL suspended in 




number, the approximate number of cells in the vial, the date and the name of the 
individual performing the freezing protocol. 100 μL of dimethyl sulfoxide (DMSO) was 
pipetted to the bottom of the vial, followed by 900 μL of cell suspension from the 
aforementioned passaging protocol. The mixture was re-suspended once, followed by a 
quick addition of 300 μL of FBS to the top of the solution, with no resuspension. 
Cryovials were then capped and placed into a -80oC freezer in a specialized 
cryocontainer for at least 24 hrs, to slowly cool the cell suspensions, before placing the 
vials into a separate container in the -80oC freezer or liquid nitrogen for long term 
storage.  
2.6 – HUVEC Activation with TNF-α 
For experimentation, it was necessary to determine how best to simulate 
inflammatory mediator production in the HUVEC culture. Different concentrations of 
TNF-α were titrated out to determine a concentration that would activate the cells 
without causing cell death. Concentrations of 1 ng/mL, 10 ng/mL, 25 ng/mL and 50 ng 
TNF-α were tested for 4, 8, 16, 24, 48 and 72 hours in order to determine the best way 
to activate the cells. To create these dilutions a TNF-α stock of 10,000 ng/mL was 
dissolved into the appropriate amount of media, depending on the flask size.  
2.7 – Ferment, Secretome and Supernatant 
Bacterial secretome, milk ferment and conditioned macrophage supernatant was 
obtained from Dr. Julia Green Johnson’s lab and diluted into medium for titration. To 




Man, Rogosa and Sharpe agar (MRS) in order to ensure that the cells reach maximal 
density before being moved into Roswell Park Memorial Institute (RPMI) medium to 
culture for 23 hours. Following this incubation period, the bacterial suspension was then 
spun down in a centrifuge in order to remove the bacterial cells from the medium. This 
“cell-free” medium is then filtered to remove all peptides 10 kilodaltons (kDa) or larger 
as it has been shown by Dr. Julia Green-Johnson’s lab that it was the smaller peptides 
(i.e. <10 kDa) that exerted the anti-inflammatory/ beneficial effect on gut epithelial cells. 
This allowed for the testing of untreated L. rhamnosus protein secretions on endothelial 
cell biomarker production.  
Store bought 3.25% homogenized milk was used to prepare the milk ferments. 
The milk was exposed to 1x108 CFU/mL of L. rhamnosus and allowed to incubate, with a 
non-fermented milk control and a lactic acid acidified milk control, at 37oC until the 
fermenting milk reached a pH of 4.7+/- 0.1. For our purposes, it was necessary to have 
the milk ferment filtered in order to remove the L. rhamnosus as we were unsure of the 
potential detrimental effects that direct exposure to the bacteria would have on our 
cells. Additionally, if the acidified controls required further acidification, HCl was added 
in order to decrease the pH to match the L. rhamnosus fermented milk. 
 Macrophage supernatant was acquired by removing the conditioned medium 
produced by type 0 macrophages during culture with milk ferments. Monocytes were 
differentiated into type 0, or resting, macrophages by exposing THP-1 cells to 100ng/mL 
of phorbol-12-myrisate-13-acetate (PMA) for 48 hours at 37oC and 5% CO2. Following 




media and L. rhamnosus ferment. Whole and filtered ferment was added to the now 
adherent THP-1 macrophages for 24 hours before being removed and stored for later 
use.  Dilutions of 1/10, 1/100 and 1/1000 of the secretome, ferment, and supernatant 
and 1/25 of the supernatant were diluted into culture media for analysis of cell 
response.  
2.8 – Incubation Conditions  
Incubations with each of the secretome, ferment, supernatant and peptide interventions 
and TNF-α were investigated as either a pre-incubation, post-incubation or co-
incubation. Pre-incubation involved intervention incubation prior to the addition of TNF-
α, post-incubation involved activating the cells prior exposing it to the compounds and 
the co-incubation involved exposing the cells to the intervention and the TNF-α 
simultaneously. It was important to do this in order to determine if the protective 
effects of the secretome, ferment, supernatant to peptides acted in either a protective, 
interfering or restorative fashion. This was important to determine how the 
interventions acted biologically in the presence of an inflammatory event.  
Prior to incubation with TNF-α, bacterial secretome, milk ferment or macrophage 
supernatant, HUVEC cells were grown for a minimum of 8 days in supplemented MCDB 
131 medium. An estimated confluency of >80% was necessary in order to maintain cell 
density necessary for optimal execution of the flow cytometry protocol. Population and 




through the Trypan Blue Exclusion assay explained above. Optimum culture conditions 
were achieved when media was changed every Monday, Wednesday and Friday.  
Table 1: Description of Incubation Conditions 
 First 24 or 72 hours (Whole 
macrophage supernatant only) 
Second 24 hours 
Pre-Incubation: 
Incubation first with bacterial 
secretome, L. rhamnosus 
fermented milk, or macrophage 
supernatant followed by 
incubation with TNF- α diluted into 
supplemented MCDB131 media 
Dilutions of: 
- 1/10, 1/100, and 1/1000 
of bacterial secretome 
- 1/100, 1/1000 of L. 
rhamnosus fermented 
milk  
- 1/25, 1/100 of whole and 
filtered fermented milk 
respectively  
Diluted in supplemented MCDB131 
media 
10ng/mL TNF- α diluted in media  
from 10000ng/mL TNF- α stock 
solution 
Post Incubation: 
Incubation first with TNF- α diluted 
into supplemented MCDB 131 
media followed by incubation with 
bacterial secretome, L. rhamnosus 
fermented milk or macrophage 
supernatant 
10ng/mL TNF- α diluted in media  
from 10000ng/mL TNF- α stock 
solution 
Dilutions of: 
- 1/10, 1/100, and 1/1000 
of bacterial secretome 
- 1/100, 1/1000 of L. 
rhamnosus fermented 
milk  
- 1/25, 1/100 of whole and 
filtered fermented milk 
respectively  
Diluted in supplemented MCDB131 
media 
Co-Incubation: 
Simultaneous incubation with TNF- 
α and bacterial secretome, L. 
rhamnosus fermented milk or 
macrophage supernatant diluted 
into supplemented MCDB 131 
media 
Dilutions of: 
- 1/10, 1/100, and 1/1000 
of bacterial secretome 
- 1/100, 1/1000 of L. 
rhamnosus fermented 
milk  
- 1/25, 1/100 of whole and 
filtered fermented milk 
respectively  
As well as 
- 10ng/mL TNF- α from 
10000ng/mL stock 
Diluted in supplemented MCDB131 
media 
Dilutions of: 
- 1/10, 1/100, and 1/1000 
of bacterial secretome 
- 1/100, 1/1000 of L. 
rhamnosus fermented 
milk  
- 1/25, 1/100 of whole and 
filtered fermented milk 
respectively  
As well as 
- 10ng/mL TNF- α from 
10000ng/mL stock 









2.9 – Peptide Incubations 
 We received synthesized peptides from the lab of Dr. Janice Strap at 
concentrations of 100 μg/mL. Peptide fractions were diluted into MCDB 131 
supplemented medium. Final concentrations of 3 μg/mL and 10 μg/mL were used for 
each peptide tested. 
Table 2:  List of peptides synthesized from β-casein and used in experimental exposures to 
endothelial cells. 
 Peptide MW (g/mol)  
P1 VPP 311.38 Nakamura, 
1995 




1851.18 Tellez, 2010 
P4 HQPHQPLPPT 1151.3 Tellez, 2010 
P5 WMHQPHQPLP
PT 
1468.71 Tellez, 2010 
P6 LYQEPVLGPVR 1270.51 Tellez, 2010 
P7 LDQWLCEK 1034.2 Tellez, 2010 
P8 YP 278.31 Yamamoto, 
1999 
P9 PGPIPN 593.69 Boutrou, 2013; 
Migliore-
Samour 1989 
P10 FFVAP 579.7  
P11 KVLPVP 651.85  
P12 KVLPVPQ 779.99  
 
2.10 – Cell Viability 
Cell viability was assayed using the Trypan Blue cell exclusion assay both before 




following cell challenge. Following cell dissociation from the flask during the passaging 
protocol (used both to seed new flasks and test for viability), 50 μL of cell suspension 
was transferred to a micro-centrifuge tube and mixed with 50 μL of Trypan Blue. This 
mixture was resuspended by pipetting up and down approximately 6 times to ensure 
thorough mixing. 15 μL of the Trypan Blue suspension was added to a hemocytometer, 
and cells were counted through the use of an inverted microscope. All cells were 
counted in the 4 corner and 1 centre square of the hemocytometer and cell viability was 
estimated by subtracting the number of blue (dead) cells from the total number of cells 
counted, and then dividing this new number by the total number of cells and multiplying 
by 100% (T-D = Y, Y/T x 100% = viability). As long as viability was 85% or higher, 
experiments continued.  
2.11 – ELISA Protocol  
The following protocol was used for the MCSF, MCP-1 and sICAM-1 ELISA antibody from 
R&D. Plates were prepared by diluting the capture antibody, whose concentration will 
change depending on the antibody used in PBS (360 μg/mL to 2.0 μg/mL for MCSF, 120 
μg/mL to 1.0 μg/mL for MCP-1, 720 μg/mL to 4.0 μg/mL for sICAM-1). This capture 
antibody dilution was then used to coat a 96-well microplate with 100 μL per well before 
the plate was placed in the fridge overnight to allow the capture antibody to adhere to 
the plate. The following morning, the plate was thoroughly shaken into the sink to 
remove excess liquid, prior to each well then being washed three times using R&D wash 
buffer formulation (0.05% Tween20 in PBS, pH 7.2-7.4) to ensure that no unbound 




against paper towel placed on the lab bench in order to completely remove the wash 
buffer from the plate. 100 μL (full well plate) or 50 μL (half well plate) of standards 
(MCSF, MCP-1 or sICAM-1) and samples were placed in the plate, in triplicate, following 
the pre-arranged “96 well plate map”. After the addition of standards and samples, the 
plate was allowed to incubate at room temperature for 2 hours in order to allow the 
cytokines, chemokines and biomarkers of interest to bind to the capture antibody in the 
plate. Following the 2 hr room temperature incubation the plate was, again, washed 
three times using the R&D wash buffer and dried. The once again dry plate was then 
incubated with the detection antibody, which was diluted in reagent diluent to the 
concentration required by each of the three respective kits (36 μg/mL to 200 ng/mL for 
MCSF, 3.0 μg/mL to 50 ng/mL for MCP-1, 18 μg/mL to 100 ng/mL for sICAM-1). 100 μL 
(full well plate) or 50 μL (half well plate) of the detection antibody suspension was 
placed in each of the 96 wells, and the plate was then incubated at room temperature 
for a further 2 hours. After a third washing/drying step, 100 μL (full well plate) or 50 μL 
(half well plate) of HRP/streptavidin, which is the secondary antibody used to capture 
and cleave the substrate, diluted in reagent diluent, was added to each of the wells, put 
in a drawer in order to limit its exposure to light, and left to incubate for 20 minutes at 
room temperature. Following this incubation step, the final washing/drying step was 
carried out and followed by the addition of 100 μL (full well plate) or 50 μL (half well 
plate) of TMB, the substrate that will cause the color change. The final incubation was 
also carried out in a drawer for 20 minutes at room temperature, followed by 100 μL 




activate the color change. The plates were then read in a plate reader at 450 nm 
wavelength. R&D protocols call for the use of a “full well plate” and therefore full 
volumes of antibody and samples, ½ well plates can, in some cases, provide better, more 
accurate results.  
2.12 – Flow Cytometry 
Experimental incubations, as listed above, were carried out in 25 cm2 tissue culture 
flasks in order to ensure sufficient cell population of ~106 cells for successful flow 
cytometric analysis. Cells were first removed from the flasks using either of the two 
passaging methods mentioned above. For this particular application, passaging with 
trypsin was especially useful due to the rapid dissociation of the HUVECs from the tissue 
culture flasks. After the neutralization and centrifugation step (section 2.3.2), the media 
was aspirated from the Falcon tube and the cell pellet was resuspended in 1mL of PBS. 
Two microcentrifugation tubes are prepared for each experimental population to be 
used for both the detection antibody and for the control antibody. The detection 
antibody used was ICAM-1 (CD54) and the control was immunoglobulin G (IgG) 
conjugated with phycoerythrin (PE), the fluorescent molecule used for detection. Due to 
the large size of HUVEC cells, they were dehydrated to ensure their fit into the needle of 
the GUAVA flow cytometer. In each tube 40 μL of formaldehyde (final concentration of 
2-4%) was added to 500 μL of cell suspension in PBS in order to fix surface proteins. 
HUVEC cells were then allowed to sit in the PBS/formaldehyde mixture for 10 minutes at 
37oC, followed by 1 minute on ice. Before cell permeabilization, the fixation mixture was 




micro-centrifuge at 300xg for 10 minutes at 4oC and carefully aspirated so as not to 
disturb the pellet. Following their careful aspiration, cells were re-suspended in 90 μL of 
100% ice cold methanol mixed with 10 μL of PBS and chilled on ice for 30 minutes. The 
tubes were then placed in a -20oC freezer overnight in order to fully permeabilize and 
shrink HUVEC cells. The following day, the methanol was removed from the cells by 
microcentrifugation in the aforementioned centrifuge at 4oC at 300xg for 10 minutes. 
Incubation buffer was then prepared by mixing 2 mL of FBS, 2 mg of BSA and 38 mL of 
PBS together, vortexing thoroughly to ensure that all the BSA has been removed and 
placed on ice until required. Following the first spin down step after permeabilization, 
the cell tubes were kept on ice at all times. While being careful not to disrupt the pellets, 
the permeabilization mixture was removed from each microcentrifuge tube and the 
remaining pellets were resuspended in 1mL of incubation buffer described previously. 
This “wash step” of centrifuging and resuspending in incubation buffer was repeated 
twice more for a total of 3 washes. After aspirating the final wash step, each pellet was 
resuspended in 100 μL of the incubation buffer to block for 10 minutes. Cells were 
combined with either the detection antibody or the control antibody at the appropriate 
dilutions noted on their respective anti-body data sheets, and the cells were thoroughly 
resuspended by pipetting. The detection antibodies are conjugated to a fluorophore that 
is light sensitive, thus care was taken to minimize exposure to light  the tubes were then 
placed back on ice before being placed into a dark cupboard for 1 hour at room 
temperature for the antibodies to bind appropriately. Following the required incubation 




centrifugation before finally being suspended in 500 μL of PBS. This PBS suspension was 
then analyzed using the GUAVA flow cytometer.  
2.13 – Nitric Oxide Assay 
 The Cayman Chemical Nitrate/Nitrite assay kit allows for measurement of total 
nitric oxide production by causing a color change in the presence of the NO metabolites 
nitrate and nitrite. Prior to the initiation of the Nitric Oxide assay, a 96 well plate was 
incubated with 12 peptide fractions, synthesized from the sequence of β-casein, gifted 
to us from Dr. Janice Strap’s lab. 96-well plates have 0.32 cm2 of available growth area 
which allowed for a population density of HUVEC amounting to approximately 12,800 
cells on average per well. Reagents were prepared as per the instructions of the Cayman 
Chemical Nitrate/Nitrite Assay kit. Plate maps were laid out prior to the initiation of any 
peptide addition into the media. In the blank well, 200 μL of Assay buffer or milliQ water 
was added, with no other reagents being added for the duration of the Assay. 80 μL of 
media from peptide conditioned HUVEC cells was placed in the 96 well assay plate, in 
triplicate, as well as the prepared standard, in triplicate. 10 μL of nitrate reductase 
enzyme cofactor mixture was placed in each well, followed by 10 μL of nitrate reductase. 
The plate was then covered with an adhesive strip and left to incubate, at room 
temperature, for 2 hours. After the required incubation time, the adhesive strip was 
removed and 50 μL of Greiss Reagent 1 (Sulfanilic Acid) was added to each well followed 
by 50 μL of Greiss Reagent 2 (Azo Dye). After the addition of the Azo compound, a pink 




to sit for 10 minutes for the colour to develop and then read at 540nm using a plate 
reader (Bio-Tek). 
2.14 – Statistical Analysis 
Statistical analysis was performed on any tests repeated in triplicate. Indexed one way 

















3.0 - Results 
3.1 – Optimization of HUVEC culture and experimental conditions: 
Human Umbilical Vein Endothelial Cells (HUVEC) are primary endothelial cells 
taken directly from umbilical veins. In order to ensure that they would be suitable for 
repeated testing, the cell culture protocol was optimized. Discovery of adequate culture 
conditions (i.e. media supplementation and collagen coating) allowed for the reliable 
culture of the HUVEC to ensure that tests carried across passages would not only be 
usable, but biologically relevant. 
Determining optimal conditions for activation of the HUVEC was important to 
allow analysis of the biomarkers of inflammation. A baseline biomarker expression was 
established in order to analyze the secretome, ferments, supernatant or peptide’s 
effects (appendix 1). A balance between activation and cell viability was necessary to 
establish, as too much TNF-α, while activating the cells, would have reduced the number 
of viable cells, while too little would have produced such a small effect that effects due 
to the ferment components would have been difficult to analyze. Exposure to 10 μg/mL 
of TNF-α for 24 hours was determined to be optimal for HUVEC activation (appendix 1) 
3.2 – Bacterial Secretome 
Bacterial secretome dilutions were adopted from Julia Green Johnson’s 
laboratory to match those that had down-regulatory effects on IL-8 production by the 
HT-29 IECs. It was decided, though, that lower concentrations be tested to examine 




cells were assayed using both R&D immune-linked enzyme assay and GUAVA immuno-
fluorescent cytometry assay. Cells were assayed for expression of cytokines and 
chemokines macrophage colony stimulating factor (MCSF), monocyte chemoattractant 
protein 1 (MCP-1) and soluble intercellular adhesion molecule 1 (sICAM-1) as well as the 
surface markers intercellular adhesion molecule 1 (ICAM-1) and intercellular adhesion 
molecule 2 (ICAM-2).  sICAM-1 pre-incubation experiments and MCP-1 co-incubation 
experiments were performed in triplicate and statistically analyzed through one way 
ANOVA using the SigmaPlot statistical analysis program, while MCSF and MCP-1 pre-
incubations were performed in duplicate. Conditioned media was removed every 24 
hours during the pre-incubation and post-incubation experiments in order to assess the 
individual effects of TNF-α and bacterial secretome dilutions on the HUVECs expression 
of inflammatory biomarkers and after 48 hours for co-incubation experiments. Removed 
media was stored in a -80oC freezer for at least 24 hours prior to use in the R&D Enzyme 
Linked immunosorbent assay kits (ELISA). Figure 1 (Fig.1) represents MCSF expression 
levels for 24 hours of bacterial secretome pre-incubation plus an additional 24 hour 
incubation with 10ng/mL TNF-α. There was a significant increase in the level of the 
inflammatory biomarker MCSF produced following activation with 10ng/mL TNF-α 
however, there was no change in MCSF levels seen with secretome pre-incubation 
compared to acidified control incubation. This pattern was also seen in that levels of 
sICAM-1 produced by HUVEC did not decrease with the secretome pre-incubation 
(Fig.2). The MCP-1 levels produced by HUVEC cells were not different between any of 




seen again for MCP-1 in the secretome co-incubation, as the levels of MCP-1 shown by 
the cells were not significantly different between any of the incubation conditions. 
Therefore for MCP-1 and sICAM-1, at least, incubation of HUVEC cells with bacterial 
secretome did not significantly alter the levels of inflammatory cytokines produced by 
HUVEC cells when activated compared to controls (figs 3-4). Although we were not able 
to statistically analyze MCSF and MCP-1 secretome pre-incubation experiments, it is 












Fig 1: ELISA analysis of the immunomodulatory effects of bacterial secretome pre-
incubation on production of MCSF by HUVEC. For all treatments including media control, 
HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, tissue 
culture treated 6 well plates (Falcon) and allowed to grow to a confluent monolayer over 
8 days. Confluent wells containing HUVEC cells were incubated for 24 hours using either 
plain supplemented MCDB 131 media, 1/100 or 1/1000 dilutions of bacterial secretome, 
filtered to be <10kDa (<10), or acidified lactic acid control (AC) diluted into 3 mL of 
MCDB131 media. Following the first 24 hour incubation, the secretome supplemented 
media was replaced with 3 mL of MCDB131 media supplemented with 10 ng/mL TNF-α 
diluted from a 10,000 ng/mL TNF-α stock. Experiments were repeated in duplicate and 
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Fig 2: ELISA analysis of the immunomodulatory effects of bacterial secretome pre-
incubation on production of MCP-1 by HUVEC. For all treatments, including media 
controls, HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 6 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. Confluent wells containing HUVEC cells were incubated for 24 
hours using either plain supplemented MCDB 131 media, 1/100 or 1/1000 dilutions of 
bacterial secretome, filtered to be <10kDa (<10) or acidified lactic acid control (AC) 
diluted into 3 mL of MCDB131 media. Following the first 24 hour incubation, the 
secretome supplemented media was replaced with 3 mL of MCDB131 media 
supplemented with 10 ng/mL TNF-α diluted from a 10,000 ng/mL TNF-α stock. 




























Fig 3: ELISA analysis of the immunomodulatory effects of bacterial secretome pre-
incubation on production of sICAM-1 by HUVEC. For all treatments, including media 
controls, HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 6 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. Confluent wells containing HUVEC cells were incubated for 24 
hours using either plain supplemented MCDB 131 media, 1/100 or 1/1000 dilutions of 
bacterial secretome, filtered to be <10 kDa (<10), or acidified lactic acid control (AC) 
diluted into 3 mL of MCDB131 medium. Following the first 24 hour incubation, the 
secretome supplemented media was replaced with 3 mL of MCDB131 media 
supplemented with 10 ng/mL TNF-α diluted from a 10,000 ng/mL TNF-α stock. 
Experiments were repeated in triplicate and tested for significance using the SigmaPlot 


























Fig 4: ELISA analysis of the immunomdulatory effects of Bacterial Secretome Co-
incubation on production of MCP-1 by HUVEC. For all treatments, including media 
controls, HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 6 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. Confluent wells containing HUVEC cells were incubated for 48 
hours using either 3mL of plain supplemented MCDB 131 media (0ng/mL), 3 mL of 
MCDB 131 media containing 10ng/mL TNF-α (10ng/mL), 1/100 or 1/1000 dilutions of 
bacterial secretome (<10) or acidified lactic acid control (AC) diluted into 3 mL of 
MCDB131 media or 1/100 or 1/1000 dilutions of bacterial secretome (<10) or acidified 
lactic acid diluted into 3mL supplemented MCDB131 media containing 10ng/mL TNF-α. 
Experiments were repeated in triplicate and tested for significance using the SigmaPlot 

























3.3 – Conditioned Macrophage Supernatant 
The effects of conditioned macrophage supernatant on TNF-α activated HUVECs 
were assayed using both the ELISA assay and the GUAVA immuno-fluorescent cytometry 
assay. Cells were assayed for the cytokines, chemokines and surface markers 
macrophage colony stimulating factor (MCSF), monocyte chemotactic protein 1 (MCP-1), 
soluble intercellular adhesion molecule 1 (sICAM-1), and intercellular adhesion molecule 
2 (ICAM-2). In the pre-incubation and post-incubation experiments, conditioned HUVEC 
media was removed every 24 hours to assess the individual effects of TNF-α and 
supernatant on the cells. In the co-incubation experiments media was removed after 48 
hours in order to assess the combined effects of simultaneous TNF-α and macrophage 
supernatant exposure on the HUVEC. All experiments, save for the ICAM-2 cytometric 
analysis, were performed in triplicate and the results were analyzed through one way 
ANOVA through the Sigma Plot statistical analysis program. 
Fig. 5 represents the effects of a 24 hour filtered macrophage supernatant and 
TNF-α co-incubation on the expression of ICAM-2 by HUVEC. The effects of the co-
incubation were analyzed using the GUAVA flow-cytometry assay mentioned above. This 
assay was done in an attempt to identify a surface marker that may have responded 
better to stimulation with the macrophage supernatant. The 1/100 dilution of the 
supernatant, but not the acidified control appeared to increase the expression of ICAM-
2 on the surface, but the presence of TNF-α greatly reduced this expression. The 
macrophage supernatant appeared unable to dampen the effects of TNF-α activation 




Figures 6-8 represent the effect of a 48 hour incubation of filtered macrophage 
supernatant on MCSF, MCP-1 and sICAM-1 expression on TNF-α activated HUVEC. 
Following the 48 hour incubation, media was removed and frozen for at least 24 hours 
before analysis using the respective R&D ELISA kit. No significant change in cytokine 
production by α activated HUVECs was detected. 
Figure 9 represents the effects of a 72 hour whole macrophage secretome pre-
incubation on HUVEC followed by a 24 hour TNF-α activation, in order to asses if pre-
treatment might block the effects of activation. As above, following each incubation 
period media was removed and stored at -80oC for at least 24 hours in order to assess 
the individual effects of TNF-α and macrophage supernatant on HUVEC. Here, sICAM-1 
levels were analyzed using the R&D CD54/ICAM-1 ELISA kit and results were completed 
in triplicate in order to test for statistical significance. No significant change in cytokine 












Fig 5: Flow cytometric analysis of the immunomodulatory effects of Conditioned 
Macrophage Supernatant on Endothelial cell expression of Intracellular Adhesion 
Molecule 2 (ICAM-2/CD102). For all treatments HUVEC cells were seeded at a density of 
5000 cells/cm2 into vented, collagen coated 25 cm2 tissue culture flasks and allowed to 
form into a confluent monolayer over the course of 8 days. 25 cm2 flasks have a 
workable culturing area of 25cm2 which allowed for a population density of HUVEC 
amounting to approximately approximately 1-1.2 million cells per flask, on average. 
Confluent flasks containing HUVEC cells were incubated with 3mL of either: 
supplemented MCDB131 media (0ng), MCDB 131 supplemented with 1/100 dilutions of 
supernatant (Sup) or acidified control (AC), MCDB131 media supplemented with 
10ng/mL of TNF-α (10ng) or MCDB 131 media supplemented with 10ng/mL TNF-α and a 
1/100 dilution of supernatant (Sup) or acidified control (AC). Following the 24 hour co-
incubation, media was removed and stored for later analysis. The HUVEC cells remaining 
in the flask were then detached from the flask following the trypsin protocol above, and 
then fixed and read following the flow cytometry protocol mentioned above. Cell 
suspensions were read on the GUAVA flow cytometer. Cells were analyzed for levels of 
fluorescence. The greater the fluorescent intensity, the greater the amount of ICAM-2 
expression. Results were obtained once, and therefore statistical analysis was not 
possible. 
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Fig 6: ELISA analysis of the immunomodulatory effects of supernatant from 
macrophages conditioned in filtered L. rhamnosus R0011 fermented milk with TNF-α co-
incubation on production of MCSF by HUVEC. For all treatments, including media 
control, HUVECs were seeded at a density of 5000 cells/cm2 into collagen coated, tissue 
culture treated 6 well plates (Falcon) and allowed to grow to a confluent monolayer over 
8 days. 6-well plates have 9.5 cm2 of available growth area which allowed for a 
population density of HUVEC amounting to approximately 456,000 to 500,000 cells on 
average per well. Confluent wells containing HUVEC cells were incubated for 48 hours 
using either MCDB 131 media alone (0ng/mL), MCDB 131 media containing 10 ng/mL of 
TNF-α (10 ng/mL), MCDB 131 media containing a 1/100 dilution of either the 
macrophage supernatant (sup) or the acidified lactic acid control (LA). After the 48 hour 
co-incubation, media was removed from the coated collagen plate and stored in a -80oC 
freezer for at least 24 hours prior to use in the R&D MCSF ELISA assay. Experiments were 
repeated in triplicate and tested for significance using the SigmaPlot statistical analysis 

























Fig 7: ELISA analysis of the immunomodulatory effects of supernatant from 
macrophages conditioned in filtered L. rhamnosus R0011 fermented milk and TNF-α Co-
incubation on production of MCP-1 by HUVEC. For all treatments, including media 
control, HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 6 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. 6-well plates have 9.5 cm2 of available growth area which 
allowed for a population density of HUVEC amounting to approximately 456,000 to 
500,000 cells on average per well. Confluent wells containing HUVEC cells were 
incubated for 48 hours using either MCDB 131 media alone (0ng/mL), or MCDB 131 
media containing 10 ng/mL of TNF-α (10ng/mL) plus either a 1/100 dilution of the 
macrophage supernatant (Sup) or the acidified lactic acid control (AC). After the 48 hour 
co-incubation, media was removed from the coated collagen plate and stored in a -80oC 
freezer for at least 24 hours prior to use. Experiments were repeated in triplicate and 
tested for significance using the SigmaPlot statistical analysis program. No significant 



















Fig 8: ELISA analysis of the immunomodulatory effects of supernatant from 
macrophages conditioned in filtered L. rhamnosus R0011 fermented milk and TNF-α Co-
incubation on production of sICAM-1 by HUVEC. For all treatments, including media 
controls, HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 6 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. Confluent wells containing HUVEC cells were incubated for 48 
hours using either MCDB 131 media alone (0ng/mL), or MCDB 131 media containing 
10ng/mL of TNF-α (10ng/mL) plus a 1/100 dilution of either the macrophage 
supernatant (sup) or the acidified lactic acid control (LA). After the 48 hour co-
incubation, media was removed from the coated collagen plate and stored in a -80oC 
freezer for at least 24 hours prior to use in the R&D MCSF Enzyme Linked 
immunosorbent assay (ELISA). Experiments were repeated in triplicate and tested for 





















Fig. 9 ELISA analysis of the immunomodulatory effects of 72 hour pre-incubation of 
supernatant from macrophages conditioned in L. Rhamnosus R0011 whole milk followed 
by a 24 hour incubation with 10ng/mL TNF-α on production of sICAM-1 by HUVEC. For all 
treatments, including media controls, HUVEC cells were seeded at a density of 5000 
cells/cm2 into vented, collagen coated t-25 tissue culture flasks and allowed to form into 
a confluent monolayer over the course of 8 days. Confluent flasks containing HUVEC 
cells were incubated with 10mL of either: supplemented MCDB131 media (0ng, 10ng 
TNF-α), MCDB 131 supplemented with 1/25 dilutions of supernatant (Sup) or acidified 
control (AC) for 72 hours. Following this 72 hour pre-incubation flasks were then 
exposed to either supplemented MCDB 131 media (0ng/mL or 0ng/mL TNF-α plus a 1/25 
dilution of supernatant) or supplemented MCDB 131 media containing 10ng/mL TNF-α 
(10ng/mL or 10ng/mL plus a 1/25 dilution of supernatant). Media was then removed 
from the tissue culture flasks and stored for at least 24 hours at -80oC before use in the 
R&D ELISA protocol described above, specified for sICAM-1. Experiments were repeated 
in triplicate and tested for significance using the SigmaPlot statistical analysis program.  
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3.4 – Nitric Oxide Production 
Effects of synthesized milk ferment proteins (bioactive peptides) on production of the 
vasodilator NO by endothelial cells were assessed using the Cayman Nitrate/Nitrite 
assay kit, which measures the stable metabolites of NO production. Nitrate and nitrite 
are markers of NO production and measured due to the fact that NO only exists for 
approximately 30 seconds, making it impossible to measure with a colorimetric assay. 
Measurements of the total nitrate and nitrite levels give an estimate of the total NO 
produced by the HUVECs, as the main anti-inflammatory mediator released by 
endothelial cells is nitric oxide. The experiment was carried out in two phases. The first 
was to assess the NO production by HUVECs during exposure to <10 kDa fraction of L. 
helveticus, L. rhamnosus, and their associated non acidified (NAC) and acidified controls 
(AC). The fractions were placed into the media at dilutions of 0.1 μg/mL, 1 μg/mL, 3 
μg/mL and 10 μg/mL for 24 hours. Following that 24 hours, the 96 well plates containing 
the HUVEC and HUVEC conditioned media were shaken to mix the nitrate and nitrite 
into the media. Figure 10 shows the increase in NO production by HUVEC exposed to 10 
μg/mL of <10 kDa fractions of L. helveticus and L. rhamnosus fermented milk as well as 
their acidified (AC) and non-acidified (NAC) controls.  
The second phase involved 12 synthesized peptides derived from the sequence of β-
casein, obtained from Bio Basic, and diluted into MCDB 131 supplemented media. Each 
peptide has been shown to have ACE inhibitory activity (Nakamura, 1995; Tellez, 2010; 
Yamamoto, 1999; Boutrou, 2013; Migliore-samour, 1989) and were identified from the 




lactotripeptides valyl-prolyl-proline (VPP) and isoleucyl-prolyl-proline (IPP), which are 
peptides liberated from β-casein by L. helveticus and S. cerevisiae. Both have previously 
been shown by Hirota et al (2011) to induce NO production by endothelial cells and 
were therefore used as positive controls. The HUVEC were incubated with the peptides 
at dilutions of 3 μg/mL and 10 μg/mL for 24 hours.  The cells were not activated by TNF-
α for this test as we were not assessing the HUVECs in an inflammatory state. As can be 
seen below (Fig. 11 & 12) peptides 4 and 9 showed the greatest effect on the amount of 
NO production by endothelial cells, over control and were similar in NO production 
levels to known peptides VPP & IPP. Figure 12 shows a direct comparison of peptides 4 
and 9 (HQPHQPLPPT and PGPIPN respectively) to VPP and IPP. Statistical analysis shows 
each peptide elicits more NO production than control and that NO production by 
peptides HQPHQPLPPT and PGPIPN is not statistically different from known vasodilators 















Fig 10. Effect of >10kDa fractions of milk fermented with L. helveticus and L. rhamnosus 
on untreated HUVECs. HUVEC cells were seeded at a density of 5000 cells/cm2 into 
collagen coated, tissue culture treated 96 well plates (Falcon) and allowed to grow to a 
confluent monolayer over 8 days. Confluent wells containing HUVEC cells were 
incubated for 24 hours with either 100 μL of 0.1 μg/mL, 1 μg/mL, 3 μg/mL or 10 μg/mL of 
<10 kDa fraction or of L. helveticus or L. rhamnosus, non-acidified control (NAC) or 





























Fig.11: Effect of VPP, IPP and 9 isolated synthesized peptides on NO production in 
HUVECs. HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, 
tissue culture treated 96 well plates (Falcon) and allowed to grow to a confluent 
monolayer over 8 days. Confluent wells containing HUVEC cells were incubated for 24 
hours exposed to either 100 μL of 3 μg/mL or 10 μg/mL of 12 different synthesized 
peptides, using VPP & IPP as controls. Results were obtained once and therefore 





















Fig. 12 Effect of VPP, IPP and 2 isolated synthesized peptides on NO production in HUVECs. 
HUVEC cells were seeded at a density of 5000 cells/cm2 into collagen coated, tissue 
culture treated 96 well plates (Falcon) and allowed to grow to a confluent monolayer 
over 8 days. Confluent wells containing HUVEC cells were incubated for 24 hours 
exposed to either 100uL of 3ug/mL or 10ug/mL of either VPP (1) and IPP (2) controls, or 
one of 2 different synthesized peptides; HQPHQPLPPT (P4) and PGPIPN (P9). After the 24 
hour incubation period the 96 well plates were shaken and 80uL of the conditioned 
media was transferred to a second 96 well plate and the nitric oxide assay was 
performed using Cayman’s Nitrate/Nitrite Assay kit as described above. The nitric oxide 
assay was repeated in triplicate and tested for significance using the sigma plot 






























4.1 – Exposure to Bacterial Secretome does not result in down regulation of 
inflammatory biomarker production by HUVECs  
 Exposure of HUVECs to the bacterial secretome of L. rhamnosus was important 
as a control to test for the effects of proteins that bacteria would secrete normally. 
However, as can be seen in figures 1-4, the bacterial secretome did not seem to have 
any effect on the HUVEC at all, either when activated by TNF-α or not. These 
experiments tested whether proteins from the bacteria could have effects on the cell; 
further experiments are now focussed on the effects of proteins from milk ferments and 
peptides, not products from the bacteria themselves.  
4.2 – Exposure of HUVECs to Macrophage Supernatant does not result in down 
regulation of inflammatory biomarker production  
 The macrophage supernatant tests were done using the secreted compounds 
from macrophages conditioned with either whole milk ferment, which contained L. 
rhamnosus cells, or filtered milk ferment, which had the L. rhamnosus cells filtered from 
it. Monocytes were first cultured in the laboratory of Dr. Julia Green-Johnson before 
being differentiated into M0 macrophages. Monocytes are cells that grow in suspension, 
but upon differentiation become adherent.  These macrophages were then challenged in 
milk fermented with L. rhamnosus bacteria in one of two ways. Either the macrophages 
were incubated with exposure of whole ferment, which means that the fermented milk 
still contained the L. rhamnosus bacteria that fermented it, or they were incubated in a 
filtered fermented milk that had the bacteria filtered out of it. Using the whole and 




supernatant and thus investigate indirect effects on HUVEC cells. As shown in (Fig. 6- Fig. 
9) the whole and filtered macrophage supernatant had no effect in preventing the 
endothelial cell secretion of sICAM-1, MCP-1 or MCSF as inflammatory molecules when 
co-incubated with 10 ng/mL TNF-α as challenge. The supernatant from cultured 
macrophages was a biological model that was tested in our study as a way to determine 
if products from these immune cells were altering HUVEC cell behaviour. Macrophages 
are found in the circulation during both healthy and inflamed states so it stands to 
reason that both the macrophages and their secreted products would be in close 
proximity to endothelial cells. We began this experiment optimistic that the 
macrophages would, upon exposure to milk ferments, secrete some protective signals 
that would exert an anti-inflammatory effect in an indirect manner on the HUVEC cells. 
In order to condition themselves and maintain immunity, macrophages will travel 
through the circulation to the GALT (gut associated lymphoid tissue) and extend 
processes out into the gut lumen. When we consume fermented milk products like 
yogurt or fermented milk drink, we are consuming not only the peptides from the milk 
itself but the healthy bacteria that cleaved milk proteins. This means that when the 
macrophages reach out they are being conditioned by the peptides and the bacteria. 
Then, as opposed to their secretions, the bacterium themselves or bioactive peptides 
making their way into the circulatory system, may each potentially mediate their effects 
by causing changes in the macrophages (Bermudez-Brito et al. 2014). Here we tested the 
effects of the supernatant of the macrophages. As can be seen with figure 6 to figure 9, 




either positively or negatively once the HUVECs were activated by TNF-α. Once the 
HUVEC were exposed to the pro-inflammatory TNF-α, they seemed to stay activated in a 
pro-inflammatory state for at least 48 hours, which was the duration of the co-
incubation test. Tellez et al (2010) showed that macrophages exposed to “cell free” L. 
helveticus fermented milk increased production of inflammatory biomarkers, suggesting 
that conditioned supernatants may contain further inflammatory signals. It may then be 
possible that macrophages increase production of cytokines in response to fermented 
milk, perhaps as a way to prime or modulate the immune system for more immediate 
action during infection. Work ongoing in our group has suggested that milk conditioned 
with L. rhamnosus appears to condition the macrophages into a regulatory phenotype, 
characterized by an increase in regulatory cytokines (M. Jeffrey, personal 
communication) 
Next steps for this project would be to put the M0 macrophages in direct contact 
with the HUVECs after they have been conditioned with the L. rhamnosus fermented 
milk to investigate if direct contact is necessary. There is still a possibility that once 
conditioned, the macrophages prepared in Dr. Julia Green-Johnson’s lab may be able to 
exert an anti-inflammatory effect on endothelial cells once they have a chance to adhere 
to them directly and this is proposed as a future extension of this project. Since TNF-α 
stimulation of HUVECs results in profound activation, another approach would be to co-
culture with ferment exposed macrophages and investigate production of anti-
inflammatory biomarkers or changes in gene expression. This would allow investigation 




pathways as well as examining the decreased expression of pro-inflammatory cytokines. 
Marcone et al. (2015) describe an adhesion assay using THP-1 monocytes, as a method 
for testing the adhesive nature of activated macrophages and the effects that bioactive 
peptides have on those interactions. The methodology may be pursued in order to 
determine the effects that L. rhamnosus fermented milk fractions play on the interaction 
between activated HUVEC and monocytes/macrophages. 
4.3 – Exposure to Synthesized Peptide from β -casein Sequence shows NO production 
by cultured endothelial cells 
 As was mentioned in the introduction, it has been shown that bioactive peptides 
can have a direct role to play in the prevention of atherosclerosis and cardiovascular 
disease (Donkor et al. 2007; Fekete et al. 2013; Papadimitriou et al. 2007; Hirota et al. 
2011; Qian et al, 1995). Three suggested mechanisms for bioactive peptides’ 
physiological role are: ACE-inhibition, NO release and interference in thrombus 
formation. (Phelan and Kerins, 2011). However, the ability of a bioactive peptide to exert 
any of these effects is dependent on which bacteria are responsible for its liberation 
during fermentation and also on the method of consumption. Specifically with the 
research discussed in this thesis, the bioactive peptides are proposed to be produced 
through the cleavage of β-casein by L. helveticus lactic acid bacteria (See Table 2). This is 
one of the many bacteria that have been shown to have potential angiotensin 
converting enzyme (ACE) inhibitory activity and thus it was important to test the effects 
of specific peptides in isolation. Of the 12 synthesized peptides obtained from the lab of 
Dr. Janice Strap, 2 peptides had an effect on NO production by endothelial cells greater 




production by endothelial cells (Hirota et al. 2011) and have angiotensin converting 
enzyme (ACE) inhibitory activity in vitro (Nakamura, 1995), were used as positive 
controls. While not exceeding levels seen with VPP and IPP, HQPHQPLPPT (peptide 4) 
and PGPIPN (peptide 9) did show a moderate induction of [NO] when co-incubated with 
HUVECs. Why these peptides have an effect over others is still unknown; however these 
two sequences do show some similarities to VPP and IPP. Specifically, peptide 4 
possesses two prolines at the C-terminal end and peptide 9 contains the sequence PIP, a 
rearrangement of IPP. Peptide 4 (HQPHQPLPPT) was initially identified by Tellez et al. 
(2010), and its effects were tested on a murine macrophage cell line. Peptide 4 was one 
of 5 peptides identified from an L. helveticus fermented milk fraction is reported to have 
significant effects on cytokine release by the murine macrophage cell line RAW 264-7 
(Tellez et al.   2010). Along with IL-6 and TNF-α release, which are hypothesized to act to 
prime the immune system, NO was also released supporting our results seen in fig. 12 
using a human endothelial cell line. Peptide 9 also shows the ability to induce NO 
production by human cells; since it possessed the amino acids PIP in its sequence, it is 
intriguing to speculate that the dipeptide IP may be in action, although the mechanism is 
not known. Further investigations into peptide 9 and its signaling effects on HUVECs 
should be pursued.   
4.4 – Human Umbilical Vein Endothelial Cells (HUVECs) 
 
Culturing Human Umbilical Vein Endothelial Cells (HUVEC) was a very challenging aspect 




methods to ensure the cells grow properly and at the appropriate rate. Ideally, HUVECs 
need a minimum of 8 days to grow to a confluent monolayer and be ready for use in 
experiments. Special attention to passaging was developed to mitigate lysing of cells 
upon each passage with trypsin. Cells received from Cedarlane were only viable for ~15 
population doublings. This is different than 15 passages. The cells could only double 
their population 15 times and this doubling was only based on the number of cells 
available.  When the majority of cells would lyse during passaging, the number of viable 
cells making it into the new culture flask was sparse. This lack of population density 
meant that in order for the HUVECs to populate a flask they had to divide more than 
normal, making the passage numbers misleading. Typically HUVEC cells are only viable 
for experimentation from passage 2 to passage 5, possibly 6 if the flasks have been 
seeded at a density higher than the recommended 5000 cells/cm2. By having the cells 
lyse and decrease in population during passaging they exceeded their doubling limit well 
before the passage number indicated they should have. This issue also arose when we 
began using Cellstar tissue treated cell culture flask as, even though the flasks were 
treated specifically to allow most cell types to grow and thrive, there was still a problem 
with cells adhering to the plastic. This problem was solved by providing the flasks with a 
layer that works to imitate the basal lamina (found in the blood vessels) between the 
bottom of the flasks and the adherent cells. By coating the tissue culture flasks in 
collagen this not only provided a layer for the cells to adhere to so that they would not 
become stuck to the plastic, but also gave them access to proteins that allowed them to 




minute incubation of supplemented MCDB131 prior to the addition of the HUVEC cells 
meant that when added, the HUVEC had everything they needed in order to adhere and 
propagate without sticking and lysing later. The addition of collagen also made 
passaging easier. When Accutase or more concentrated trypsin/EDTA were added, it 
dissolved the collagen by cleaving the peptide bonds that held it together. This released 
the HUVEC into suspension without ever having to manipulate the cells directly. Due to 
the extended propagation time of the HUVECs and the multiple cell culture problems; 
troubleshooting their growth took a significant amount of time. However, the final result 
was a very efficient and effective culture protocol that optimized later work. Lastly, 
ELISA and Flow Cytometry protocols were optimized for use with HUVEC. It was 
important to ensure that cell populations were large enough that the flow cytometry 
washing protocol wouldn’t totally eliminate the cell population, while also being small 
enough that we could easily test multiple ferment components without using media at 
an irresponsible rate. Additionally, it was discovered that the HUVECs were too large to 
fit into the needle attached to the flow cytometer. In order to work around this we 
employed a fixation/dehydration protocol that allowed us to ensure any biomarkers 
stayed on the surface of the cell available for antibody adhesion, but dehydrated the 
cells to a point where they would easily fit through the GUAVA flow cytometer needle. 
 HUVEC are obtained directly from umbilical cords and immediately frozen down 
for culture later. This means that we are as close to donated human tissue as we could 




endothelial cells and human microvascular endothelial cells (HMEC) are available cell 
lines for research, as was seen previously in the literature. 
4.5 – Importance of Interventions for Cardiovascular Disease/Metabolic 
Syndrome/Diet/Diabetes 
Cardiovascular disease, atherosclerosis, obesity, the metabolic syndrome and the 
other so called diseases of civilization are seemingly here to stay. The abundance of 
processed, fatty, greasy and generally unhealthy food stuffs makes winning the war on 
unhealthy lifestyles seem insurmountable. The rates of obesity and incidence of 
cardiovascular disease have risen over the last 30 years (Flegal et al, 1998; Statistics 
Canada, 2011c), and continues to be a major health concern for the future. Additionally 
as third world countries continue to industrialize and become further exposed to more 
modern approaches to living, businesses have been making a push to provide their 
overly processed unhealthy foods to this emerging market (Curtis and McCklusky, 2007). 
If the populations of these countries begin to regularly consume Western type diets, 
rates of obesity and cardiovascular disease will increase and the “unhealthy lifestyle 
epidemic” will continue to worsen. It is, therefore, incredibly important to find easily 
executable interventions as quickly as possible in order to proactively prevent an 
unnecessary increase in deaths associated with atherosclerosis, obesity, cardiovascular 
disease and diabetes. Effort should first be placed on educating the public on the 
dangers of over-consumption, or consumption of diets too high in fatty foods, with 
available options for healthy alternatives and knowledge of nutritional benefits of foods 
such as dairy products. Along with this, exercise should also be recommended and 




Finding ways to supplement already popular foodstuffs is also an easy, and ideal, 
method to help prevent the insidious effects of an unhealthy diet. While it is possible to 
achieve weight loss through exercise, reversing more insidious consequences of poor 
dietary choices like the cardiovascular disease risk, fatty streak formation or 
atherosclerotic processes take more time. This time could be reduced or made more 
efficient by using components found in foods that have been shown to have beneficial 
effects on heart health. A systematic review by Fekete et al (2013) concluded that more 
robust, well designed randomized control trial are necessary to confirm the benefits of 
milk peptides on health as the existing evidence is limited and warrants further 
investigations 
4.6 – Investigating mechanisms of fermented milk products’ effect is important for 
CVD interventions 
 Fermented milk products have been shown to have beneficial effects on heart 
health (Sonestedt et al, 2011) but, so far, the mechanisms through which these products 
exert their effects have yet to be elucidated. Their importance, though, cannot be 
understated. A few of the most important examples of fermented products available 
immediately and to the widest population demographics are yogurt and fermented milk 
drinks, the latter of which are fast becoming part of North American diets, but have 
been more popular in Asian countries. Focusing on yogurt, though, we are presented 
with a very prevalent example of a fermented milk product that could be easily added 
into North American diets in order to assist with the lifestyle changes that are necessary 
for the prevention and treatment of cardiovascular disease, atherosclerosis and other 




dietary staple or supplement that will assist in combatting cardiovascular disease. The 
discovery of what exactly makes yogurt so beneficial to heart health inform people of 
exactly why they should be incorporating it into their diet and, in turn, potentially alter 
consumption habits. Through the study of fermented dairy products like fermented milk, 
yogurt and various cheeses, we are working towards identifying novel peptides that 
seem to exert a cardio/athero-protective/preventative effect on the circulatory system. 
Identification of these peptides and a confirmation that they continue to exert their 
effects in isolation would be a benefit for its incorporation into functional foods. With 
isolation and characterization of components that make these products protective, 
supplementation of food with bioactive peptides and components could be proposed as 
an important health benefit. In this way, we make the idea of a healthy lifestyle change 
easier and less obtrusive to current lifestyles. Studying fermented milk products will, 
ideally, allow for us to come up with better preventative methods to promote heart 
health. 
 However, it seems as though that bioactivity in vivo cannot be established solely 
through in vitro experimentation (Saito et al, 2000; Abubakar et al, 1998). As was shown 
by Sonsetedt et al (2011) it is not just fermented milk that carries with it bioactive 
peptides and associated health benefits. Cheese, butter and cream, while not being at 
the level of fermented milk, still exert their own cardioprotective effects suggesting that 
the way someone consumes dairy products also plays a role in the overall health 
benefits of dairy products. Fekete et al (2013) reviewed several studies that showed 




vitro, but lose all effect when consumed and assessed in vivo. The ability of isolated bio-
active peptides to survive digestion and which peptides are consumed play a large role 
in whether or not these peptides will be able to have cardio-protective effects for 
humans. Discovery of specific foods that best protect and carry isolated bio-active 
peptides, and allow them to display the full breadth of their health promoting effects 
will open up a new category of functional foods.  
4.7 –Future directions 
 This project aimed to fill knowledge gaps in understanding how our endothelium 
responds to bioactive components of milk ferments, chemokines produced by 
macrophages, bacterial and isolated milk peptides through the measurement of 
modulation of cytokine release. Endothelial cells play an important role as the 
gatekeepers of the vascular system. They decide which cell types move in and out of 
circulation. Issues arise when determination of appropriate cell type and movement is 
compromised, a situation referred to as endothelial dysfunction. Investigating the 
endothelial cell’s role in slowing macrophage accumulation and foam cell formation 
beneath the endothelial barrier of the blood vessels can be expanded to include other 
cell types and mechanisms. As our blood flow encounters branch points, the modulation 
in shear stress upon the vessel surface is enough to allow endothelial cells to become 
dysfunctional and allow the entrance of leukocytes.  Our circulatory system has a 
plethora of branch points which are necessary in sending blood around our bodies; this 
makes endothelial dysfunction by shear stress a fact of life. Slowing the response of 




component of the vascular wall that plays an incredibly important role in the 
pathogenesis of atherosclerosis is smooth muscle (Kumar et al, 2007). Smooth muscle 
would be an important cell type to look at to bolster the results of the peptide NO 
assays. NO is both a potent anti-inflammatory and vasodilator. Assuming that the 
release of NO by the endothelial cells through exposure to bioactive peptides, would 
enact a vasodilatory function on the smooth muscle, this would cause widening of the 
vessels at areas prone to atherogenesis and might relieve some of the effects of shear 
stress on the vessels. In fact, Hirota et al (2011) showed that VPP and IPP caused 
vasorelaxation in isolated rat aorta. If these effects could be duplicated using novel 
bioactive peptides either alone, or in reversal of induced vasoconstriction, it would 
comprise a preventative function of bioactive peptides on vascular smooth muscle. 
Smooth muscle would also be an ideal next candidate for consideration due to its role in 
the pathogenesis of atherosclerosis. Once the fatty streak has progressed and foam cells 
have started to accumulate underneath the endothelial barrier, smooth muscle cells 
react to the accumulation of lipids and foam cells by starting to propagate (Zettler et al, 
2003) and release MCSF to call for more monocytes to change to macrophages (Shimada 
et al, 1992). An investigation into the effects on vascular smooth muscle might begin 
with a measurement of MCSF secretion levels and cell proliferation. 
Further investigation into smooth muscle cell responses to bioactive peptides would 
yield important information about effects on smooth muscle cells role in thrombus 
formation. The true danger with atherosclerosis is the thromboembolism, the end stage 




smooth muscle cells to the circulation, the clotting process/ coagulation cascade begins 
and a blood clot forms at the damaged site (Marmur et al, 1992). Eventually this clot, 
through the function of may be dislodged from the atherosclerotic site and make its way 
through the circulation until it arrives at a smaller vessel, becomes stuck, and begins 
impeding blood and therefore oxygen from arriving at that site. It is this blockage that 
causes the ischemic cardiovascular disease mentioned earlier and that could eventually 
proceed to cause a heart attack. Discovering if bioactive peptides have any effect on 
smooth muscle’s activation and incorporation into the atherosclerotic plaque would be 
an interesting future direction. 
Experiments may also include investigations into possible modification of 
macrophage scavenger receptors (so that they do not consume ox-LDL) or anti-oxidant 
properties of the peptides that would slow the formation of ox-LDL so the incidence of 
foam cell formation decreases. Testing the effects of bioactive peptides on LDL 
cholesterol would lead to more knowledge concerning either the direct anti-oxidant 
properties or how they may interfere with scavenger receptors of macrophages would 
also be a potential research path for the future (Hernández‐Ledesma et al, 2005). It has 
been shown, previously, that isolated peptides from L. helveticus fermented β-casein 
fraction exert an anti-oxidant effect twice as potent as the vitamin E derivative, trolox 
(Stressler et al, 2013). If bioactive peptides exerted this anti-oxidant effect on LDL, they 
would interfere with the formation of ox-LDL, and the rate of macrophages changing to 




way that they prevent macrophages from recognizing and consuming ox-LDL, therefore 
preventing their transformation into foam cells.  
 Finally, it is very compelling that a recent report by Marcone et al (2015) showed 
inhibition of pro-inflammatory cytokine production in TNF-α activated cultured 
endothelial cell lines at much higher concentrations than described here. It is possible 
that in our incubations of 3-10 μg/mL of peptide was too dilute to exert an effect. It has 
been shown that pre-incubation of human aortic endothelial cells with 30-300ug/mL of 
<5kDa proteins from Enterococcus hydrolyzed milk results in downregulation of ICAM-1, 
VCAM-1 and e-selectin gene and cell surface protein expression (Marcone et al, 2015). 
The net amount of peptide present may be a key determinant to that fraction’s effect. 
Leclerc et al (2002) showed that 1-2.5 g/kg of caseinate rich L. helveticus (R211 and 
R389) fermented milk showed significant reductions in mean arterial blood pressure 
over a 24 hour period in spontaneously hypertensive rats. Increasing the protein 
concentrations in our incubations would potentially produce different results, although 
the focus on biologically relevant concentrations may be lost.   
4.8 – Conclusion 
 Fermented milk has been shown by Sonestedt et al (2011) to exert cardio-
protective or anti-atherogenic effects. In our experiments, 2 bioactive peptides 
synthesized from the β-casein sequence showed moderate effects of NO production, a 
potent vasodilator and anti-inflammatory compound, release by HUVECs. In order to 
confirm and expand these results, experiments should look further into the preparation 




change depending on the milk used, the bacteria used and the method of ingestion. In 
this project we focused specifically on bioactive peptides produced by L. rhamnosus, a 
lactic acid bacteria suggested to produce bioactive peptides that exert ACE-inhibitory 
effects. While their effects on inflamed endothelial cells at low concentrations were not 
robust, their anti-inflammatory activity will require further investigation to fully 
elucidate any mechanisms. It will be important to discover whether or not the effects of 
the bioactive peptides produced by L. rhamnosus change depending on the method of 
consumption, as in vitro and in vivo effects can differ (Sonestedt et al, 2011). As 
cardiovascular disease and atherosclerosis become more and more prevalent with a 
worldwide shift towards a modern diet, it is becoming increasingly more important to 
discover interventions that will combat the more insidious effects of high fat diets. 
Discovery of functional foods that will assist in protecting our cardiovascular system 
from the damaging effects of free radicals and atherosclerosis will be a step in the right 
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